×
Dogwood Therapeutics EBITDA 2020-2024 | DWTX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Dogwood Therapeutics ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Dogwood Therapeutics EBITDA 2020-2024 | DWTX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Dogwood Therapeutics ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$174.7B
Vertex Pharmaceuticals (VRTX)
$125B
Regeneron Pharmaceuticals (REGN)
$112.1B
Bristol Myers Squibb (BMY)
$107B
Gilead Sciences (GILD)
$106.8B
CSL (CSLLY)
$97.4B
GSK (GSK)
$80.7B
Alnylam Pharmaceuticals (ALNY)
$36.9B
Argenex SE (ARGX)
$32.6B
BioNTech SE (BNTX)
$27.9B
Biogen (BIIB)
$27.9B
Illumina (ILMN)
$23.5B
Moderna (MRNA)
$22B
BeiGene (BGNE)
$21.7B
Genmab (GMAB)
$15.3B
BioMarin Pharmaceutical (BMRN)
$13.4B
Exact Sciences (EXAS)
$12.9B
Vaxcyte (PCVX)
$12.9B
Insmed (INSM)
$12.8B
Incyte (INCY)
$12.8B
Sarepta Therapeutics (SRPT)
$11.8B
Bio-Techne Corp (TECH)
$11.7B
QIAGEN (QGEN)
$10B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.8B
Legend Biotech (LEGN)
$8.2B
Revolution Medicines (RVMD)
$8.2B
Exelixis (EXEL)
$8.1B
Repligen (RGEN)
$8.1B
Intra-Cellular Therapies (ITCI)
$7.9B